Had a second consultation at UCSF today.
- If the V600E BRAF mutation test is positive, my UCSF oncologist's recommendation would be to pursue experimental therapy with a B-RAF inhibitor first. The idea would be to try to keep me stable as long as possible, since there's a lot of promising experimental therapies in the pipeline, say, next year and beyond. He said there might be some role for DTIC (Dacarbazine) as well. He feels the experimental B-RAF treatments are more prolonging to my stability than IL-2 treatment in the short-term and, IL-2 could be done at any time, whereas experimental trials have more limited recruiting periods.
- If the melanoma instead is a wild type, his recommendation would be look for C-KIT and N-RAS mutations next, which almost never co-exist with the B-RAF mutation. IL-2 would also be promoted at this point to, perhaps, a first-line therapy.
- A treatment he doesn't believe in is biochemotherapy (a combination of low-dose IL-2 with other chemotherapy agents). Frying bone marrow is as bad as it sounds, and 5 randomized clinical trials to date have not shown a positive outcome. No reason to do something nasty just for the sake of doing something. I'm happy to scratch that one off the list.
- Another doctor that was present indicated that some molecular / mutation profiling of my melanomas over time may be worthwhile at some point (2001, 2008 and 2010 tissue samples so far.)
Comments
Post a Comment